PIN Pharma to Present a Poster at Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival

NEW YORK--()--PIN Pharma, a pre-clinical immunotherapy company focused on modulating the immune system in oncology, today announced the Company will be presenting PIN-2: A Novel Immunopriming Peptide with Immunomodulatory Activity Linking the Innate and Adaptive Immune Systems at Poster Session B on Monday, September 26, 2016 from 5:30 pm – 8:00 pm.

About PIN Pharma, Inc.

PIN Pharma is a pre-clinical stage venture backed immunotherapy company focused on the development of PINS (precision immune stimulants). The lead compound PIN-2 is a first-in-class, novel, next-generation engineered peptide that empowers the immune system in vivo. The Company’s technology primes the innate immune system to modulate adaptive immunity thereby generating and expanding antigen-specific cytotoxic T-cells in vivo. The company is advancing PIN-2 to the clinic early first quarter 2017.

For more information about PIN Pharma and PIN-2, contact Mark Smith, CBO ( or Colin Bier, CEO ( at PIN Pharma, Inc., 3960 Broadway, Suite 620, New York, NY, or call 212-543-2583.


PIN Pharma, Inc.
Mark Smith, CBO
or Colin Bier, CEO

Recent Stories

RSS feed for PIN Pharma, Inc.